Mike J. Crawford
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial.
Crawford, Mike J.; Leeson, Verity C.; Evans, Rachel; Barrett, Barbara; McQuaid, Aisling; Cheshire, Jack; Sanatinia, Rahil; Lamph, Gary; Sen, Piyal; Anagnostakis, Katina; Millard, Louise; Qurashi, Inti; Larkin, Fintan; Husain, Nusrat; Moran, Paul; Barnes, Thomas R.E.; Paton, Carol; Hoare, Zoe; Picchioni, Marco; Gibbon, Simon
Authors
Verity C. Leeson
Rachel Evans
Barbara Barrett
Aisling McQuaid
Jack Cheshire
Rahil Sanatinia
Dr Gary Lamph g.lamph@keele.ac.uk
Piyal Sen
Katina Anagnostakis
Louise Millard
Inti Qurashi
Fintan Larkin
Nusrat Husain
Paul Moran
Thomas R.E. Barnes
Carol Paton
Zoe Hoare
Marco Picchioni
Simon Gibbon
Abstract
Background:
Data from case series suggest that clozapine may benefit inpatients with borderline personality disorder (BPD), but randomised trials have not been conducted.
Methods:
Multicentre, double-blind, placebo-controlled trial. We aimed to recruit 222 inpatients with severe BPD aged 18 or over, who had failed to respond to other antipsychotic medications. We randomly allocated participants on a 1:1 ratio to receive up to 400 mg of clozapine per day or an inert placebo using a remote web-based randomisation service. The primary outcome was total score on the Zanarini Rating scale for Borderline Personality Disorder (ZAN-BPD) at 6 months. Secondary outcomes included self-harm, aggression, resource use and costs, side effects and adverse events. We used a modified intention to treat analysis (mITT) restricted to those who took one or more dose of trial medication, using a general linear model fitted at 6 months adjusted for baseline score, allocation group and site.
Results:
The study closed early due to poor recruitment and the impact of the COVID-19 pandemic. Of 29 study participants, 24 (83%) were followed up at 6 months, of whom 21 (72%) were included in the mITT analysis. At 6 months, 11 (73%) participants assigned to clozapine and 6 (43%) of those assigned to placebo were still taking trial medication. Adjusted difference in mean total ZAN-BPD score at 6 months was -3.86 (95% Confidence Intervals = -10.04 to 2.32). There were 14 serious adverse events; 6 in the clozapine arm and 8 in the placebo arm of the trial. There was little difference in the cost of care between groups.
Interpretation:
We recruited insufficient participants to test the primary hypothesis. The study findings highlight problems in conducting placebo-controlled trials of clozapine and in using clozapine for people with BPD, outside specialist inpatient mental health units.
Citation
Crawford, M. J., Leeson, V. C., Evans, R., Barrett, B., McQuaid, A., Cheshire, J., …Gibbon, S. (2022). The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial. Therapeutic Advances in Psychopharmacology, 12, 1-14. https://doi.org/10.1177/20451253221090832
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 11, 2022 |
Online Publication Date | Apr 29, 2022 |
Publication Date | 2022-04 |
Deposit Date | Feb 26, 2024 |
Journal | Therapeutic advances in psychopharmacology |
Print ISSN | 2045-1253 |
Publisher | SAGE Publications |
Peer Reviewed | Peer Reviewed |
Volume | 12 |
Pages | 1-14 |
DOI | https://doi.org/10.1177/20451253221090832 |
Keywords | borderline personality disorder, clinical trial, clozapine |
Publisher URL | https://journals.sagepub.com/doi/10.1177/20451253221090832 |
PMID | 35510087 |
You might also like
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search